Sometimes the best way to save a failing organ is to build a temporary replacement and hook it up outside the body. That's the concept behind United Therapeutics Corp (UTHR), which announced Monday that its external liver assist product successfully supported five patients with acute liver failure through a Phase 1 clinical trial.

The device, called miroliverELAP, is essentially a bioengineered liver that lives outside your body while doing liver things. Developed by Miromatrix Medical, a wholly owned subsidiary of United Therapeutics, the system combines an external blood circuit with a single-use engineered liver designed to provide temporary support when someone's own liver decides to stop working.

Building a Liver From Scratch (Sort Of)

Here's where it gets interesting from a bioengineering perspective. The team takes a porcine liver and strips out all the pig cells, leaving behind just the structural scaffold. Then they repopulate that scaffold with human endothelial cells and human liver cells harvested from donated human livers that weren't suitable for transplantation. These donated organs come from organ procurement organizations and would otherwise go unused.

So you end up with a pig-shaped framework filled with human cells, functioning as a liver outside the patient's body while their blood circulates through it.

Early Trial Results Look Encouraging

The Phase 1 study enrolled five patients with acute liver failure who weren't candidates for a liver transplant. Each patient received miroliverELAP treatment for at least 44 hours, and the device met its primary endpoint: keeping patients alive during the study period.

Just as importantly, researchers reported no unexpected serious adverse events over the subsequent 32-day follow-up period. For patients facing dire circumstances with few options, this kind of temporary liver support could be genuinely life-saving.

The company plans to present and publish full study results in the second half of 2026, which should give us a more detailed picture of how well the device performed and what challenges remain.

Where the Stock Stands

United Therapeutics shares are showing some mixed technical signals. The stock is trading 2.7% below its 20-day simple moving average and 2.5% below its 50-day SMA, but sits 3.7% above its 100-day SMA, suggesting some longer-term strength. Over the past 12 months, shares have climbed approximately 26.89% and are currently positioned closer to their 52-week highs than lows.

The RSI reading of 39.40 puts the stock in neutral territory, while MACD is below its signal line, indicating bearish pressure. The combination suggests momentum is somewhat mixed at the moment.

• Key Resistance: $512.50
• Key Support: $470.00

What Analysts Expect for Earnings

Investors are looking ahead to the company's next earnings report on February 25, 2026. Analysts are expecting earnings per share of $6.82, up from $6.19 in the same quarter last year, and revenue of $810.08 million, up from $735.90 million year-over-year.

EPS Estimate: $6.82 (Up from $6.19 YoY)

Revenue Estimate: $810.08 Million (Up from $735.90 Million YoY)

Analyst Consensus: Buy Rating ($447.43 Avg Price Target)

Performance Scorecard

Looking at United Therapeutics' comparative strengths against the broader market reveals some interesting patterns:

• Value Rank: 61.88 — The stock is fairly valued relative to peers
• Quality Rank: 75.91 — The company maintains a strong balance sheet
• Momentum Rank: 86.84 — The stock is outperforming the broader market

The Verdict: United Therapeutics shows a strong momentum setup combined with solid quality fundamentals. While the valuation appears fair rather than cheap, the high momentum score indicates the stock is riding a favorable trend.

ETFs Holding Significant UTHR Positions

• Invesco S&P MidCap Quality ETF (XMHQ): 3.55% Weight
• First Trust Health Care AlphaDEX Fund (FXH): 2.44% Weight
• Simplify Health Care ETF (PINK): 3.24% Weight

Price Action: UTHR stock was up 0.44% at $471 during Monday's premarket session.